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Purpose: Age-related macular degeneration (AMD) is a major cause of blindness in older adults and has a genetically
complex background. This study examines the potential association between single nucleotide polymorphisms (SNPs) in
the glucose transporter 1 (SLC2A1) gene and AMD. SLC2A1 regulates the bioavailability of glucose in the retinal pigment
epithelium (RPE), which might influence oxidative stress–mediated AMD pathology.
Methods: Twenty-two SNPs spanning the SLC2A1 gene were genotyped in 375 cases and 199 controls from an initial
discovery cohort (the Amsterdam-Rotterdam-Netherlands study). Replication testing was performed in The Rotterdam
Study (the Netherlands) and study populations from Würzburg (Germany), the Age Related Eye Disease Study (AREDS;
United States), Columbia University (United States), and Iowa University (United States). Subsequently, a meta-analysis
of SNP association was performed.
Results: In the discovery cohort, significant genotypic association between three SNPs (rs3754219, rs4660687, and
rs841853) and AMD was found. Replication in five large independent (Caucasian) cohorts (4,860 cases and 4,004 controls)
did not yield consistent association results. The genotype frequencies for these SNPs were significantly different for the
controls and/or cases among the six individual populations. Meta-analysis revealed significant heterogeneity of effect
between the studies.
Conclusions: No overall association between SLC2A1 SNPs and AMD was demonstrated. Since the genotype frequencies
for the three SLC2A1 SNPs were significantly different for the controls and/or cases between the six cohorts, this study
corroborates previous evidence that population dependent genetic risk heterogeneity in AMD exists.
Age-related macular degeneration (AMD) is the most
common cause of severe visual impairment in Western
countries, rendering the disease a major public health issue
[1,2].
The prevalence of AMD increases strongly with age,
affecting 4% of the population over the age of 60 and more
than 10% of individuals older than 75 [2,3]. The early stages
of the disease are characterized by drusen, focal depositions
of extracellular material in Bruch’s membrane beneath the
retinal pigment epithelium (RPE) [4,5]. Late stages of the
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disease include two forms: an atrophic form (geographic
atrophy [GA]) and an exudative form (choroidal
neovascularization [CNV]).
AMD has a multifactorial etiology [6]. Age, smoking
history, high body mass index, hypertension, and
hypercholesterolemia influence AMD predisposition [7]. The
importance of genetic risk factors for AMD was highlighted
in several recent studies. In addition to the complement factor
H (CFH) gene, genetic association studies consistently
implicated at least four complement genes (factors B [CFB]
and I [CFI], components 2 [C2] and 3 [C3]) as well as one of
two genes (ARMS2 and HTRA1) in the chromosomal region
10q26. Taken together, these data suggest that the
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complement system, oxidative stress, mitochondrial function,
and extracellular matrix turnover play a role in AMD [8–14].
The RPE is one of the key tissues involved in AMD and
functions in several processes that are vital for preserving
sight. The RPE layer constitutes the outer blood-retinal barrier
and regulates transport ions, fluid, and metabolites between
the retina and the choroid [15]. Among other things, the RPE
transports glucose to the photoreceptors. Glucose supply to
the photoreceptors is essential since glucose is the preferred
energy substrate for the metabolically highly active retina
[16]. The sodium-independent glucose transporter SLC2A1 is
the predominant glucose transporter in the retina [17,18].
SLC2A1 localizes to the apical and basolateral membranes of
the RPE [19]. According to Beatty and colleagues, the retina
is the ideal environment for generating free radicals and other
reactive oxygen species [20]. This may occur through similar
transport mechanisms through the inner and outer blood retina
barriers, and makes the retina an environment susceptible to
oxidative damage. Fernandes et al. showed in 2011 that
sustained oxidative stress can result in decreased glucose
transport in retinal endothelial cells [21]. On the other hand,
increased glucose transport and SLC2A1 expression are
upregulated by hypoxia as shown by Takagi et al. [22].
Finally, increased serum glucose (hyperglycemia) might lead
to impaired antioxidant protection [23] and increased reactive
oxygen species (ROS) production [24]. In conclusion, DNA
sequence variations or altered expression levels in SLC2A1
may influence glucose delivery to the retina and thereby
profoundly affect local oxidative stress.
Variants in SLC2A1 have been associated with diabetic
retinopathy [25], type 2 (non-insulin-dependent) diabetes
[26], diabetic nephropathy [27,28], and clear-cell renal cell
carcinoma [29]. Finally, expression of SLC2A1 in the retina
and brain is altered in different pathophysiological conditions,
including hypoxia [22,30], Alzheimer disease [31], and
epilepsy [32]. We hypothesized that genetic variants in
SLC2A1 could influence the glucose transport capabilities of
this transporter. This would lead to changes in the glucose
level in the RPE and neural retina, and alter the local oxidative
burden. Since multiple studies suggest that oxidative stress is
implicated in AMD [20,33–35], we performed an extensive
case-control association analysis, to test whether SLC2A1
gene variants are associated with this devastating disorder.
METHODS
Study populations: We employed five case-control studies
and one prospective cohort study, consisting of a total of 5,235
AMD cases and 4,203 ethnically- and age-matched control
subjects. The studies were approved by the Ethics Committees
of the Academic Medical Center Amsterdam, the Erasmus
Medical Center Rotterdam, the University of Würzburg, the
Age Related Eye Disease Study (AREDS) Access Committee,
and the Institutional Review Boards of Columbia University,
and the University of Iowa. All studies followed the tenets of
the Declaration of Helsinki, and all participants provided
signed informed consent.
The initial discovery sample, the Amsterdam-Rotterdam-
Netherlands (AMRO-NL) study population, consisted of 375
unrelated individuals with AMD and 199 control individuals.
Subjects were all Caucasian and recruited from the Erasmus
University Medical Centre, Rotterdam, and the Netherlands
Institute for Neuroscience, Amsterdam, the Netherlands [36].
The second sample, the Rotterdam Study, is a prospective
cohort study aimed at investigating chronic diseases in older
adults, as previously described [37]. The eligible population
comprised all inhabitants aged 55 years or older of a middle-
class suburb in Rotterdam, the Netherlands.
The third sample, the Franconian AMD study (Würzburg,
Germany), consisted of 612 cases and 794 age-matched
control subjects; the cases and controls originated from the
lower Franconian region of Bavaria, Germany [38].
The fourth sample, the AREDS (United States), included
two parts: 1) a randomized clinical trial to assess the effect of
supplemental antioxidants on risk of AMD and cataract,
which began in April 1992 and ended in November 2001; and
2) a longitudinal study of progression of AMD. The study
participants were Caucasian, aged 55 to 80 years, and were
recruited at 11 centers in the United States from clinic and
general populations in those areas. The sample consisted of
936 individuals with AMD and 218 controls [39].
The fifth sample, the Columbia University (United
States) study population, comprised 1,104 unrelated
individuals with AMD and 368 unrelated controls of
European American descent, recruited at Columbia
University [40].
The sixth sample, the Iowa University (United States)
study population, comprised 1,139 unrelated individuals with
AMD and 403 unrelated controls of European American
descent, recruited at the University of Iowa [41].
Diagnosis of age-related macular degeneration: Subjects
from all cohorts underwent ophthalmic examination and
fundus photography as described [36–41]. Signs of AMD
were graded according to the International Classification and
Grading system for AMD [42] except the AREDS [43] and
the Franconian AMD study [38] (Appendix 1).
Single nucleotide polymorphism selection: Twenty-two SNPs
were selected that capture common variations in the
SLC2A1 gene. SNP data were from the Centre d’Étude du
Polymorphisme Humain (CEPH) population (Utah residents
with ancestry from northern and western Europe) by use of
the International HapMap Project. SNP selection was based
on criteria such as functional relevance, minor allele
frequency (MAF)>10%, coverage of the main linkage
disequilibrium (LD) blocks, and tagging of the most common
haplotypes. Tag SNPs were selected with Tagger, an option
of Haploview [44] (all SNPs were captured with an LD
tagging criterion of r2>0.8).
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Genotyping: Genomic DNA was isolated from peripheral
leukocytes after venous puncture according to standard
protocols. A total of 1,536 SNPS, including 22 SLC2A1 SNPs,
were genotyped in the AMRO-NL study population using an
Illumina GoldenGate assay on a BeadStation 500 GX
(Illumina Inc., San Diego, CA). This GoldenGate assay did
not include our previous published complement factor 5
(C5) and ERCC6 versus AMD screenings. We currently
screened all known rare and common genetic variants, which
met Illumina quality standards, in approximately 45 AMD
candidate genes (DB and AB; data not shown). The Rotterdam
Study was genotyped with the Illumina HumanHap 550K
array (Illumina Inc.). Quality control was performed using
PLINK (version 1.01) [37]. The Franconian AMD study
sample was genotyped with TaqMan SNP Genotyping assay
for the SNPs rs4660687: A>C and rs3754219: A>C.
Rs841853 was genotyped with PCR (forward primer: 5′-CCT
CAG GGA ATA AAG CTA GTC TCC AG-3′; reverse
primer: 5′-AGA CCA GCC AGA GGT TCC AAA-3′)
followed by XbaI digestion and restriction fragment length
analysis. The AREDS, Columbia, and Iowa samples were also
genotyped with Taqman SNP genotyping assays. All TaqMan
assays were performed on ABI7300 Real-Time PCR systems
(Applied Biosystems, Foster City, CA).
Statistical analysis: To account for multiple comparisons, we
determined, initially, three different significance tresholds for
the Golden-Gate Assay in the AMRO-NL study. The first was
an overall Bonferroni corrected significance threshold per
SNP (0.05/ total nr of SNPs on the Illumina GoldenGate assay
[n=1536; p=3.25 × 10−5]). However, this significance level
takes neither the large difference in the MAF of the SNPs
screened nor the co-occurrence of SNP variation in LD blocks
into account. Thus, next to this overall significance level, we
also applied a gene-wise significance threshold by dividing
the nominal alpha by the number of SNPs per gene. The gene-
wise significance threshold for SLC2A1 is 0.05/ total nr of
SLC2A1 SNPs on the Illumina GoldenGate assay (n=22;
p=2.27 × 10−3). Finally, as a positive control to determine the
true statistical significance levels of our assay, we also
included complement factor 3 (C3) polymorphisms, well
known in the literature to associate with AMD. We found an
association with multiple C3 SNPs and AMD in our study,
with p values ranging from p=0.02 to p=0.0003 (not shown).
The p values of our initial SLC2A1 association findings ranged
from p=0.02 to p=0.0006 (see the Results section).
In all studies, we employed the χ2 test to test SNP
distributions for conformity with the Hardy–Weinberg
equilibrium (HWE). We compared allele frequencies between
cases and controls using Fisher’s exact test statistic. We
estimated odds ratios (ORs) and 95% confidence intervals
(CIs) for the risk of AMD with logistic regression analysis and
represent the risk of disease (AMD versus no AMD) in the
genetic risk group divided by the risk of disease in the non-
risk group (non-carriers). For the AMRO-NL study and the
Rotterdam Study, we adjusted all ORs for age and gender. To
determine whether SLC2A1 SNPs were independent risk
factors, we estimated their effects in a model with an
additional adjustment for known (genetic) risk factors: CFH
Y402H, LOC387715 A69S, and smoking and their
interactions with the SLC2A1 SNPs. All analyses were
performed in Statistical Package for Social Sciences (SPSS)
for Windows software (release 16.0; IBM-SPSS, Inc.,
Chicago, IL). In the Rotterdam Study, we performed
association tests using logistic regression in the PLINK
software package (version 1.01) [45]. We performed a meta-
analysis using Review Manager (RevMan) Version 5.0.
assuming an additive genetic model. We tested heterogeneity
between studies using Cochran’s Q statistic [46]. In addition,
we quantified heterogeneity with the I2 metric [46]. In the
absence of heterogeneity (I2 statistic <25%), we used the fixed
effects model (the Mantel-Haenszel method) to calculate the
pooled OR; otherwise, we used the random effects model (the
DerSimonian and Laird method). We compared genotype
frequencies between the study populations with the Pearson
χ2 test.
RESULTS
The AMRO-NL sample: associations of SLC2A1 SNPs with
age-related macular degeneration: We initially genotyped 22
SNPs in 375 unrelated AMD patients and 199 controls of the
AMRO-NL study population. Demographic characteristics of
the AMRO-NL study population and all study populations
used were essentially described previously [36,47]. SNP
genotype frequencies were tested in controls and conformed
to the HWE, except for two SNPs (rs12407920, rs16830101;
p=0.04) that were removed from further analysis. HWE data,
genotype distributions, and allelic p values for the 22
SLC2A1 SNPs are presented in Table 1. Three out of the 22
SNPs showed a significant allelic association with AMD:
rs3754219 (p=0.0011), rs4660687 (p=0.0157), and
rs841853 (p=0.0006). The reported initial associations in the
AMRO-NL study did not reach the overall Bonferroni
significance threshold, but two out of three SNPs
(rs3754219 and rs841853) passed the gene-wise threshold as
well as the positive control (C3) association threshold. The
risks of AMD for these three SLC2A1 SNPs, adjusted for age
and gender, are presented in Table 2. When all AMD cases
and controls of the AMRO-NL study were included in the
analysis, we observed significant association with all three
SNPs. SNP (rs3754219) showed a protective effect for AMD
(OR 0.44; 95% CI 0.26–0.74). The other SNPs showed a risk
increasing effect (rs4660687, rs841853) with the highest ORs
seen for homozygous carriers of the risk alleles of rs841853
(OR 2.24; 95% CI 1.13–4.41). We subsequently analyzed the
early and late AMD subgroups separately. For early AMD,
we observed a significant association only for rs4660687
(Table 2). For the late AMD subgroup, we observed a similar
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effect as seen for all AMD cases: a significantly increased risk
for hetero- and homozygote carriers of rs841853 and for the
heterozygote carriers of rs4660687 and a protective effect for
homozygote carriers of rs3754219 (Table 2). Adjusting for
Figure 1. Linkage disequilibrium (LD) display in Haploview of (A) the three SLC2A1 single nucleotide polymorphisms (SNPs) rs3754219,
rs4660687, and rs841853. Left: D’(D prime), Right: r2 (r square) (B) all the 22 SNPs in the SLC2A1 gene with minor allele frequency>10%
screened in this study and illustrating the nine distinct haplotype blocks. LD scores: D' (D prime) displays the raw D' value, which is the
normalized covariance for a given marker pair and the correlation coefficient r2 (r square). Darker shades represent stronger LD.
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three prominent AMD risk factors (CFH Y402H,
LOC387715 A69S, and smoking) did not modify the relation
of any of the SLC2A1 SNPs with AMD (data not shown).
Independent replication studies have variable outcomes: The
three SNPs that showed allelic and genotypic association
(rs3754219, rs4660687 and rs841853) were selected for
replication in five study populations of comparable ethnic
(Caucasian) composition: the Rotterdam Study, the
Franconian AMD study, the AREDS, Columbia University,
and the University of Iowa. Figure 1A shows the LD map in
Haploview of the three SNPs and the corresponding LD
scores, and Figure 1B shows the LD map of all 22 SLC2A1
SNPs with minor allele frequency>10% screened in this study
and illustrates the nine distinct haplotype blocks. The three
associated SNPs are in two different blocks in the SLC2A1
gene (rs3754219 and rs841853 are in the same LD block). As
can be seen, two SNPs (rs1770811 and rs841856) without
allelic association are inside the LD block with rs3754219 and
rs841853. Obviously, the observed (non-) associations
depend on the informativeness (MAF) of the specific SNPs
and the distribution of alleles. A possible explanation might
also be differences in LD patterns (between the SNPs in the
same wild-type LD block) with an untyped causal variant.
Replication studies for SLC2A1 single nucleotide
polymorphism rs3754219: The results of replicating the
association between SNP rs3754219 and AMD (all cases or
late AMD and controls only) are presented in Appendix 2.
Genotype frequencies for rs3754219 followed the HWE in all
study populations (data not shown). When we included all
AMD cases, we observed no significant association with
rs3754219 in any of the replication cohorts. When we
analyzed the AMD subgroups separately (Appendix 3), we
found a borderline significant effect in the Rotterdam Study
for the CNV cases (p=0.0554). In line with the results of the
discovery cohort, we observed this possible protective effect
for homozygous carriers of the risk allele. In contrast, we
observed a risk increasing association effect between
SLC2A1 rs3754219 and AMD (subtype) in the Columbia
University study: This effect occurred in the homozygous
carriers of the risk allele (OR 1.66; 95% CI 1.01–2.72) in the
GA group (Appendix 3). No significant associations were
seen in the other replication cohorts.
Replication studies for SLC2A1 single nucleotide
polymorphism rs4660687: The results of replicating the
association between SNP rs4660687 and AMD (all cases or
late AMD and controls only) are presented in Appendix 2.
Genotype frequencies followed the HWE in all study
populations (data not shown). The association of rs4660687
with AMD, as found in the AMRO-NL study, was confirmed
in the Rotterdam Study (OR 1.39; 95% CI 1.12–1.72). Thus,
both Dutch populations showed a significant association for
all AMD cases. However, in the other replication cohorts, no
significant association was found. Upon subtype analysis
(Appendix 4), we found a significant association between
rs4660687 and the early AMD cases of the Rotterdam Study.
Again, this effect was present in both Dutch populations. For
this SNP, we also found a possible opposite effect: in the
Franconian AMD study, we observed a significant protective
effect in the mixed AMD subgroup instead of a risk increasing
effect. This was seen for hetero- and homozygous carriers of
the risk allele. In the three cohorts from the United States, we
found no significant associations for AMD.
Replication studies for SLC2A1 single nucleotide
polymorphism rs841853: The results of replicating the
association between rs841853 SNP and AMD (all cases or late
AMD and controls only) are presented in Appendix 2.
Genotype frequencies followed the HWE in all study
populations (data not shown). The association of rs841853
with AMD, as found in the AMRO-NL study, was confirmed
in the AREDS sample: We observed a significant effect for
homozygous carriers of the risk allele (OR 2.07; 95% CI 1.14–
3.76) in all AMD cases. In the other replication cohorts, no
significant association was found. Upon subtype analysis
(Appendix 5), we observed a significant association between
rs841853 and the CNV cases of the Rotterdam Study.
Additionally, in the AREDS sample, we observed a
significant association between rs841853 and late AMD cases
(Appendix 2). The effect was particularly profound for the
CNV and GA subpopulations (Appendix 5). Finally, in the
Columbia cohort, we found a significant association between
rs841853 and the GA cases, but this effect was in the opposite
direction: heterozygotes showed a protective association
instead of a risk increasing effect for GA. We also saw this
protective effect for the late AMD cases of the Columbia
cohort (Appendix 2). We saw no significant associations
between rs841853 and AMD subtypes in the two other study
populations.
Meta-analysis: heterogeneity of effect: We performed a meta-
analysis of the putative association between AMD and
SLC2A1 SNPs rs3754219, rs4660687, and rs841853 across
the independent study populations.
We quantified the effect and assessed the potential
heterogeneity of effect between studies (with Cochran’s Q test
and the I2 metric, Table 3 and Figure 2, Figure 3, and Figure
4). For rs3754219, significant heterogeneity of effect between
studies was demonstrated, not only for all AMD cases
combined (p=0.006; I2=70%) but also for CNV (p=0.02;
I2=65%) and late AMD cases (p=0.002; I2=73%).
Furthermore, moderate (not significant) heterogeneity was
seen for the GA and CNV + mixed cases, respectively. No
heterogeneity was found for the early and mixed AMD cases
(Table 3). For the groups with I2 values >25%, we used the
random effects model (the DerSimonian and Laird method)
to calculate the pooled OR; otherwise, in absence of
heterogeneity (I2 statistic <25%), we used the fixed effects
model (the Mantel-Haenszel method). The summary OR
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indicated that no significant association between rs3754219
and (all clinical subtypes of) AMD was found over all
populations (Figure 2). Similarly, meta-analysis for
rs4660687 showed significant heterogeneity (p=0.02;
I2=64%) for all AMD cases. Moderate (but not significant)
heterogeneity was seen for the AMD subtypes with the
exception of the GA, CNV, and CNV+ mixed cases where no
or low heterogeneity was detected (Table 3). Using a random
or fixed effects model (depending on the amount of
heterogeneity), we found no association between rs4660687
and (all clinical subtypes of) AMD over all populations
(Figure 3). Also for rs841853, the between-study
heterogeneity was significant; not only for all AMD cases
combined (p=0.008; I2=68%) but also for CNV (p=0.0005;
I2=80%) and late AMD cases compared to the controls
(p=0.002; I2=74%). We saw moderate (not significant)
heterogeneity for CNV+ mixed cases and saw no or low
heterogeneity for the early, GA, and mixed cases (Table 3).
Using a random or fixed effects model (depending on the
amount of heterogeneity), the summary OR indicated that no
significant associations were present between rs841853 and
(all clinical subtypes of) AMD (Figure 4).
Genetic heterogeneity between study populations: To explore
the genetic contribution to the heterogeneity of effect between
the populations, we assessed the differences in MAF and
genotype frequencies between the study populations (Table 2
and Appendix 2). For rs3754219, we observed MAFs in the
control populations ranging from 41% (Columbia University)
to 52% (AMRO-NL). For the cases, we observed rs3754219
MAFs varying from 41% (AMRO-NL) to 46% (Franconian
AMD study). For rs4660687, we observed MAFs in the
control populations ranging from 34% (AMRO-NL) to 43%
(AREDS). For the cases, the rs4660687 MAFs were nearly
similar (41%–43%) with the exception of the Franconian
AMD study (MAF=37%). For rs841853, the MAF ranged
from 25% (AMRO-NL) to 33% (the Franconian AMD study)
in the control groups. For the cases, we observed rs841853
MAFs varying from 30% (Iowa) to 35% (AMRO-NL).
Subsequently, we compared the genotype frequencies of the
controls between study populations for all three SNPs using
Figure 2. Meta-analysis of rs3754219 for its association with all AMD cases (A), early (B), GA (C), CNV (D), mixed (E), CNV + mixed
(F), and late AMD (G) cases in six independent study populations. AMD=age-related macular degeneration; GA=geographic atrophy;
CNV=choroidal neovascularization; Mixed cases (combination of GA + CNV). Odds ratios (ORs, squares) and 95% confidence intervals (CI;
horizontal lines) are presented for each study. Also shown is the black diamond of the summary OR using either the additive Mantel-Haenszel
fixed effects model when heterogeneity was absent (I2 <25%) or the additive DerSimonian and Laird random effects model when heterogeneity
was present (I2 >25%). Heterogeneity between studies was tested using Cochran's Q statistic and the I-square statistic for inconsistency.
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the Pearson χ2 test: for rs3754219 and rs841853, we found
significant differences with χ2 overall p values of 0.027 and
0.024, respectively (Table 4). We found no significant
differences in genotype frequencies between the control
groups for rs4660687. Next, we compared the genotype
frequencies for all populations’ cases: the rs3754219
genotype frequencies of all AMD cases combined or AMD
clinical subtypes of the six study populations did not show
significant differences. For rs4660687, we found a significant
(χ2 overall p value=0.002) difference in the genotype
frequencies of all AMD cases and the CNV+ mixed cases
(χ2 overall p value=0.049). For rs841853, we found significant
differences in the genotype frequencies for the CNV subtype
(p value=0.024; Table 4). Detailed results of the individual
analysis are presented in Appendix 6.
DISCUSSION
Three out of 22 SLC2A1 SNPs tested showed a significant
allelic and genotypic association with AMD in the AMRO-
NL discovery cohort. Replication of these three SNPs
(rs3754219, rs4660687, and rs841853) in five independent
cohorts yielded inconsistent association results. Meta-
analysis revealed no overall association between SLC2A1 and
AMD. For all three SNPs, we observed significant
heterogeneity of effect and high inconsistency across the
study populations. Using a random or fixed effect model, we
calculated pooled ORs, which were not significant for any of
the SNPs in any of the studies. Such findings are not unique:
one of the greatest challenges in interpreting genetic
association studies is the lack of consistent reproducibility
[48]. Hirschhorn and colleagues (2002) reviewed more than
600 positive associations between common gene variants and
disease and found that the majority is not robust. Of the 166
presumed associations, which were studied three or more
times, only six were consistently replicated [49]. Similarly, a
meta-analysis of 301 published studies covering 25 different
reported associations showed that less than half of the
associations were consistent across the different study
populations [50]. For AMD, at least two recent studies
highlight the lack of consistent replication of association
across large population studies: initial associations found
between AMD and SNPs in the Toll-like receptor 3 [51] and
Figure 3. Meta-analysis of rs4660687 for its association with all AMD cases (A), early (B), GA (C), CNV (D), mixed (E), CNV + mixed
(F), and late AMD (G) cases in six independent study populations. AMD=age-related macular degeneration; GA=geographic atrophy;
CNV=choroidal neovascularization; Mixed cases (combination of GA + CNV). Odds ratios (ORs, squares) and 95% confidence intervals (CI;
horizontal lines) are presented for each study. Also shown is the black diamond of the summary OR using either the additive Mantel-Haenszel
fixed effects model when heterogeneity was absent (I2 <25%) or the additive DerSimonian and Laird random effects model when heterogeneity
was present (I2 >25%). Heterogeneity between studies was tested using Cochran's Q statistic and the I-square statistic for inconsistency.
Molecular Vision 2012; 18:657-674 <http://www.molvis.org/molvis/v18/a72> © 2012 Molecular Vision
666
the Serpin Peptidase Inhibitor, Clade G, member 1
(SERPING1) genes [52] could not be replicated independently
[47,53]. For SLC2A1 SNP rs841853 and diabetic
nephropathy, a similar inconsistent association result across
large study populations was reported [54].
The SLC2A1 SNPs rs841853, rs3754219, and
rs4660687 do not reside within known regulatory region(s) of
the SLC2A1 gene (i.e., promoter, enhancers, and silencer
elements). We entered these SNPs into the SNPExpress
database to find out that these SNPs apparently indeed do not
affect gene expression. Obviously, the possibility exists that
one or more of the SNPs tag a true causal variant in or adjacent
to the SLC2A1 gene that determines the possible genetic
susceptibility to AMD. Interestingly, Tao and coworkers
(1995) examined whether the association between the
rs841853 SNP and non-insulin-dependent diabetes mellitus
could be due to other causal variants in LD with rs841853.
Initially, such a variant was not found [55]. However, after
seven years, Ng et al. (2002) found a new putative causal
variant in LD with rs841853 in an insulin-responsive enhancer
element, potentially regulating SLC2A1 gene expression and/
or function [56].
One of our study limitations is that we selected for
common SLC2A1 SNPs, with MAFs>10%. Consequently, we
could have missed variants with MAFs<10% and outside the
coding region that might influence the disease phenotype. In
addition, because our initial association values found in the
AMRO-NL study passed only two out of three significance
levels used (see Material and Methods), there was, initially, a
somewhat increased possibility of false-positive
association(s). Furthermore, as we and others have discussed
extensively elsewhere [36,57], inconsistent replication in
genetic-association studies can be caused by numerous
factors, including chance, variation in study design,
phenotypic AMD (grading) differences, and genotype errors
[58]. Indeed, the effect of these factors is stronger in small
cohorts, such as defined by clinical subtypes of AMD. These
factors may have played a role in our study [36]. In addition,
genetic heterogeneity between populations may significantly
affect the outcome of association studies [57]. It may be not
Figure 4. Meta-analysis of rs841853 for its association with all AMD cases (A), early (B), GA (C), CNV (D), mixed (E), CNV + mixed (F),
and late AMD (G) cases in six independent study populations. AMD=age-related macular degeneration; GA=geographic atrophy;
CNV=choroidal neovascularization; Mixed cases (combination of GA + CNV). Odds ratios (ORs, squares) and 95% confidence intervals (CI;
horizontal lines) are presented for each study. Also shown is the black diamond of the summary OR using either the additive Mantel-Haenszel
fixed effects model when heterogeneity was absent (I2 <25%) or the additive DerSimonian and Laird random effects model when heterogeneity
was present (I2 >25%). Heterogeneity between studies was tested using Cochran's Q statistic and the I-square statistic for inconsistency.
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coincidental that we found positive replication for SLC2A1
SNP rs4660687 in the early cases of the Dutch populations
(the AMRO-NL and the Rotterdam Study cohorts), where the
allele and genotype distributions are more or less similar, but
not in other populations.
Interestingly, we found opposite associations for the three
SLC2A1 SNPs (rs3754219, rs4660687, and rs841853) in two
highly comparable populations. A similar “flip-flop”
association was previously found by Lin et al. in two different
ethnic populations [59]. The source of this opposite effect in
our studies is not clear, and remains to be elucidated.
To assess the contribution of “the genetic factor” in detail,
we compared the genotype frequencies of all study
populations in relation to the heterogeneity of effect. The
Pearson χ2 test showed that genotype frequencies for
SLC2A1 rs3754219 and rs841853 were significantly different
for the controls of the six individual populations. For
rs4660687, we observed significant differences in genotype
distributions for the cases. For several SLC2A1 SNPs,
including rs841853, genuine genetic differences between
populations exist [27,28,60–63]. The fact that we found
significant genetic heterogeneity for three SLC2A1 SNPs in
highly comparable (Caucasian) populations strongly suggests
that the genetic contribution to the heterogeneity of effect
observed in our study is substantial.
In summary, in this study we found no consistent
significant association between three SLC2A1 SNPs
(rs3754219, rs4660687, rs841853) and AMD. The
heterogeneous findings on these three SLC2A1 SNPs provide
further evidence for population-dependent genetic risk
heterogeneity in AMD [47,51–53]. Further studies in other,
ethnically similar and diverse populations are needed to
falsify, confirm, or substantiate the potential role of SLC2A1
in AMD.
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Appendix 1. Age-related macular degeneration classification per study
sample.
AMD=age-related macular degeneration;
GA=geographic athrophy; CNV=choroidal
neovascularization; Mixed AMD=combination of GA +
CNV. To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file.
Appendix 2. Risk of AMD for SLC2A1 SNPs rs3754219, rs4660687 and
rs841853 in five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval; OR=odds ratio; SNP=single nucleotide
polymorphism; m.a.f=minor allele frequency. “A” indicates
common allele, “a” minor allele. Percentages not always add
up to 100% because of conversion to whole numbers. ORs
were estimated by logistic regression. Adjustment for age and
gender only in the Rotterdam Study. To access the data, click
or select the words “Appendix 2.” This will initiate the
download of a compressed (pdf) archive that contains the file.
Appendix 3. Risk of AMD (subgroup) cases for SLC2A1 SNP rs3754219 in
five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval; OR=odds ratio; SNP=single nucleotide
polymorphism; m.a.f=minor allele frequency;
GA=geographic athrophy; CNV=choroidal
neovascularization; Mixed AMD=combination of GA +
CNV; N.p=not performed. “A” indicates common allele, “a”
minor allele. Percentages not always 100% because of
conversion to whole numbers. ORs are estimated with logistic
regression analysis. Adjustment for age and gender only in the
Rotterdam study. To access the data, click or select the words
“Appendix 3.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 4. Risk of AMD (subgroup) cases for SLC2A1 SNP rs4660687 in
five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval; OR=odds ratio; SNP=single nucleotide
polymorphism; m.a.f=minor allele frequency;
GA=geographic athrophy; CNV=choroidal
neovascularization; Mixed AMD=combination of GA +
CNV; N.p=not performed. “A” indicates common allele, “a”
minor allele. Percentages not always 100% because of
conversion to whole numbers. ORs are estimated with logistic
regression analysis. Adjustment for age and gender only in the
Rotterdam study. To access the data, click or select the words
“Appendix 4.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 5. Risk of AMD (subgroup) cases for SLC2A1 SNP rs841853 in
five replication populations.
AMD=age-related macular degeneration; CI=confidence
interval; OR=odds ratio; SNP=single nucleotide
polymorphism; m.a.f=minor allele frequency;
GA=geographic athrophy; CNV=choroidal
neovascularization; Mixed AMD=combination of GA +
CNV; N.p=not performed. “A” indicates common allele, “a”
minor allele. Percentages not always 100% because of
conversion to whole numbers. ORs are estimated with logistic
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regression analysis. Adjustment for age and gender only in the
Rotterdam study. To access the data, click or select the words
“Appendix 5.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 6. Comparison of genotype frequencies of the controls and AMD
(subgroup) cases between all study populations.
Genotype frequencies were compared by using the
Pearson χ2 test. Abbreviations: AMD=age-related macular
degeneration; GA=geographic athrophy; CNV=choroidal
neovascularization; Mixed=combination of GA+CNV;
χ2=Chi square; df=degrees of freedom. To access the data,
click or select the words “Appendix 6.” This will initiate the
download of a compressed (pdf) archive that contains the file.
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